ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in its Phase I-B clinical trial for systemic lupus erythematosus (SLE) was administered with the dose of treatment, according to a Thursday filing with the Hong Kong bourse.
IMM0306 attaches to two specific proteins, CD47 and CD20, found on cancerous B cells and sticks more to CD20 than to CD47, making the cancer treatment more effective, the filing said.
The pharma company's shares were up by over 16%.
Price (HKD): $7.25, Change: $+1.0, Percent Change: +16.19%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments